Introduction: The utilization of sentinel lymph node (SLN) mapping technique in the management of vulval cancer is established. However, the usage of SLN mapping in the management of endometrial and cervical cancer has not yet achieved widespread acceptance. Incorporation of SLN in the management of endometrial and cervical cancer may omit the need for extensive lymphadenectomy

Objective: The purpose of this preliminary study is to evaluate the representativeness of SLN identified using Methylene blue dye and identification of adverse reaction from this procedure

Materials and Methods: All patients who have either cervical or endometrial carcinoma were recruited. They were counselled for intra-operative SLN mapping procedure. The surgical procedure was carried out in the usual manner. The SLN were identified and removed prior to completing the lymphadenectomy. The full histology of the sentinel lymph nodes was then compared with the full histology of the remaining lymph nodes removed during the systematic lymphadenectomy

Results: There were a total of 14 patients recruited in this preliminary study. Out of which 64.3% and 35.7% had endometrial and cervical carcinoma respectively. Our SLN identification rate is 100% in this preliminary study. The median number of SLN identified were two on each group of pelvic nodes i.e. the left and the right pelvic lymph nodes.  In this study, the positive predictive value (PPV) and the negative predictive value (NPV) of the SLN is 100%. There was no adverse reaction identified in all the patients during the SLN mapping procedure except the blue discolouration of urine post-procedural.

Conclusion: In this preliminary study, we have shown that, the sentinel nodes identified using Methylene blue dye are representatives of the remaining lymph nodes removed during systematic lymphadenectomy. Further study need to be carried out before this approach can be incorporated into the management of endometrial and cervical cancer.